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Abstract
Systematic reviews of randomized trials that include measurements of health-related quality of life potentially provide
critical information for patient and clinicians facing challenging health care decisions. When, as is most often the case,
individual randomized trials use different measurement instruments for the same construct (such as physical or
emotional function), authors typically report differences between intervention and control in standard deviation units
(so-called “standardized mean difference” or “effect size”). This approach has statistical limitations (it is influenced by
the heterogeneity of the population) and is non-intuitive for decision makers. We suggest an alternative approach:
reporting results in minimal important difference units (the smallest difference patients experience as important).
This approach provides a potential solution to both the statistical and interpretational problems of existing methods.
Introduction
Health-related quality of life (HRQL) is increasingly
recognized as an important outcome in randomized
trials. Disease-specific HRQL instruments provide critical
information because of their ability to detect small but
important treatment effects [1,2]. Typically, for specific
conditions, a number of disease-specific instruments are
available. For example, there are at least five instruments
available to measure HRQL in patients with chronic
obstructive respiratory disease (COPD) (Chronic Respira-
tory Questionnaire, Clinical COPD Questionnaire, Pul-
monary Functional Status & Dyspnea Questionnaire,
Seattle Obstructive Lung Disease Questionnaire,
St Georges Respiratory Questionnaire)[3].
Clinical trial investigators use different HRQL instru-
ments for various reasons, including their familiarity
with an instrument. This creates challenges for meta-
analysts seeking summary estimates in systematic
r e v i e w so ft r i a l sa d d r e s s i n gt h es a m eo rs i m i l a rH R Q L
constructs. Choices include reporting summary esti-
mates for each separate measurement instrument, or
pooling across instruments. The former approach is less
appealing in that it leaves the clinician with multiple
imprecise estimates of effect.
A widely used approach to providing summary esti-
mates across instruments - an approach endorsed by the
Cochrane Collaboration - involves dividing mean differ-
ences between intervention and control in each study by
the study’s standard deviation (SD) and calculating what
are called “standardized mean differences” (SMDs) or
“effect sizes”. Ultimately, systematic reviews using this
approach will present the magnitude of treatment effects
as SD units (e.g., pooled estimate 0.4 SD units)[4].
This approach provides a single pooled estimate of treat-
ment effect but leaves two problems. One problem is that
if the heterogeneity of patients is different in different stu-
dies, the SD will vary across studies. Therefore, given the
same true difference in HRQL between intervention and
control groups, trials with more heterogeneous patients
and similar scores on the HRQL instrument of interest
will show apparently - but spuriously - smaller effects than
trials enrolling less heterogeneous patients.
The second problem is that interpretation of the mag-
nitude of effect when represented as SD units is challen-
ging. Although rules of thumb - the most frequently used
guide tells us that an effect size of 0.2 represents a small
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ference [5] - are available, they have limitations. They are
to an extent arbitrary, and do not intuitively resonate
with either clinicians or patients [6].
One strategy to address similar problems in interpre-
t a t i o no fr e s u l t sf r o mi n d i v i d u a lt r i a l st h a tr e p o r to n
HRQL measures involves the minimal important differ-
ence (MID) [7,8]. The MID is defined as “the smallest
difference in score in the outcome of interest that
informed patients or informed proxies perceive as
important, either beneficial or harmful, and which
would lead the patient or clinician to consider a change
in the management” [9]. A variety of statistical and
anchor-based approaches to ascertaining the MID of
individual instruments are available [10].
If the MID has been established for two or more
instruments, systematic review authors could report the
results of each study in “MID units” instead of SD units
(for both individual studies and pooled effects). Standar-
dization using MIDs may provide a uniform metric that
both circumvents the fragile assumption regarding simi-
lar variability in study populations across trials that is
required for the SMD and facilitates interpretation by
both clinicians and patients. In the remainder of this
article, we will illustrate both the current and proposed
methods using data from a systematic review of respira-
tory rehabilitation in COPD [11]. Although we focus on
disease specific HRQL, the method can be applied to
any meta-analysis of RCTs that employ patient impor-
tant continuous outcome measures.
Standard methods for meta-analysis of HRQL
measures
Health Related Quality of Life scores are typically trea-
ted as continuous. In meta-analysis of continuous data,
the mean difference (MD), or the “difference in means”
i st h em e a s u r eo ft h ea b s o l u t ed i f f e r e n c eb e t w e e nt h e
mean value in each arm in a parallel group clinical trial.
When outcome measurements in all trials are made on
the same scale, a well-established inverse variance meta-
analysis method can be used to combine results across
trials and obtain a pooled MD [4].
When investigators have relied on different instru-
ments measuring the same or similar construct, it is
necessary to transform or standardize the trial results to
a uniform scale before they can be combined in a meta-
analysis. The common approach to the problem is to
calculate the SMDs for each trial (i.e., the trial MD
divided by its SD) and pool across trials.
MID method for meta-analysis of different HRQL
instruments
A potential solution to the limitations of SMD is to sub-
stitute the MID for the usual denominator of the SMD,
the SD. That is, we divide the MD by the MID that was
established for the instrument used in the trial. As a
result, rather than obtaining an estimate in SD units, we
obtain an estimate in MID units.
When we standardize by dividing the MD by the MID,
we alter the scale on which we are performing our meta-
analysis. In doing so, we also need to account for the
changes that the standardization has on the standard error
and weights associated with each standardized trial out-
come. In the accompanying appendix (additional file 1) we
derive the formulas for the variance and standard error of
the pooled MD, and provide formulas for the pooling of
results.
Application of the method
A Cochrane review of respiratory rehabilitation for
COPD included 31 trials [11] of which 16 employed two
widely used disease-specific HRQL instruments: the
Chronic Respiratory Disease Questionnaire (CRQ),[12]
and the St. Georges Respiratory Questionnaire (SGRQ)
[13]. Extensive evidence supports the validity and
responsiveness of both these instruments, and both have
established MIDs [9,14]. The authors of the systematic
review calculated separate pooled MD estimates for the
trials using the instruments’ individual “natural units”
(i.e., the 7-point scale for the CRQ and the 100 point
scale for the SGRQ [11]).
Pooled estimates for CRQ and SGRQ
Using data from the systematic review, we calculated
MDs (and 95% Confidence Intervals) separately for each
of the four domains of the CRQ and each of the three
d o m a i n so ft h eS G R Q ,a sw e l la sa no v e r a l ls c o r ef o r
each instrument. For the CRQ, most of the included
trials did not report the overall mean (SD). To resolve
this, we generated the overall mean (SD) for each trial
using the domain data provided by the Cochrane review
(see additional file 1).
For the CRQ, the pooled MD for each of the domains
(dyspnea, emotional function, fatigue, and mastery) as
well as the total score exceeded the MID, as did the
lower limit of the confidence interval for each domain
(0.5 points difference on the 7-point scale) [9]. For the
SGRQ, the pooled MD for each of the domains as well
as the total score exceeded the MID (4 points difference
on the 100-point scale) [14]. The confidence interval for
each of the domains and the overall pooled MD, how-
ever, included values less than the SGRQ’sM I Do f4 . 0
(see Table 1). The CRQ and SGRQ estimates, pooled
separately, include one study [15] that employed both
instruments. The pooled estimates in SD units are, for
the CRQ, 0.96 (95% CI 0.76, 1.16), and for the SGRQ,
0.36 (95% CI 0.12, 0.60). Combining all studies yields an
overall pooled estimate in SD units of 0.73 (95%
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2 = 58% (Figure 1). To avoid double
counting, for the overall pooled estimate in SD units
(and below for MID units), we included only the CRQ
results for Griffiths et al [15]. Although both the SGRQ
and CRQ have been widely used, and have demon-
strated validity and responsiveness in various settings;
t h er e a s o nw ec h o s et h eC R Qa st h er e f e r e n c ei n s t r u -
ment was the stronger evidence supporting the MID
and evidence of superior responsiveness [9,16].
Results in MID units
Applying the new method the pooled estimates in MID
units are, for the CRQ, 1.86 (95% CI, 1.45 to 2.27) and
for the SGRQ, 1.53 (95% CI, 0.81 to 2.24). For both
measures the common effect size exceeded 1.0 indicat-
ing that the intervention eff e c ti s ,o na v e r a g e ,a p p r e c i -
ably greater than the MID. With respect to the lower
confidence interval around the common effect size, the
CRQ results exceeded 1.0, whereas the SGRQ did not.
We can thus be confident, on the basis of the studies
using the CRQ, that the mean effect exceeds the MID
whereas, for the SGRQ we cannot. Combining all stu-
dies in MID units yields an overall pooled estimate of
1.75 (95% CI, 1.37 to 2.13), I
2 = 32% (Figure 2).
Interpreting MID unit results
The point estimate in MID units suggests a large effect
(approaching 2 MIDs) and the lower 95% CI is greater
than 1, suggesting that it is implausible that the mean
effect is less than the MID (Figure 2). However, report-
ing results in MID units risks naïve misinterpretation:
above 1 MID treatment has important benefits for all
patients, and below 1 for none. Even if the pooled esti-
mate lies between 0 and 1 (or 0 and -1), treatment may
have an important impact on many patients [17]. We
suggest the following guide for interpretation: if the
pooled estimate is greater than 1 MID, and one accepts
that the estimate of effect is accurate, many patients
may gain important benefits from treatment. If the esti-
mate of effect lies between 0.5 and 1.0, the treatment
may benefit an appreciable number of patients. As the
pooled estimate falls below 0.5 MID it becomes
Table 1 Pooled Mean Differences from Trials Included in
Cochrane Review
CRQ Point estimate (95% Confidence Interval)
Dyspnea 1.06 (0.85, 1.26)
Emotional Function 0.76 (0.52, 1.00)
Fatigue 0.92 (0.71, 1.13)
Mastery 0.97 (0.74, 1.20)
Overall 0.94 (0.57, 1.32)
SGRQ
Activities -4.78 (-1.72, -7.83)
Impacts -6.27 (-2.47, -10.08)
Symptoms -4.68 (0.25, -9.61)
Overall -6.11 (-3.24, -8.98)
Note: negative scores on the SGRQ indicate improvement.
Figure 1 Pooled Estimate in SMD Units.
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patients will achieve important benefits from treatment.
Strengths of the method
T h em a j o rs t r e n g t ho fo u rm e t h o di st h a ti ta v o i d st h e
problems associated with heterogeneity of between-
study variances (as a result of using the SD to calculate
the SMD). The MID unit approach prevents introducing
inconsistency depending on the SD of each included
trial and provides results that are likely to facilitate
intuitive interpretation by clinicians and patients. Of
interest, the statistical heterogeneity as measured by the
I
2 statistic decreased (from 58% to 32%) by reporting
results in MID units as opposed to SD units. Future stu-
dies involving formal simulation techniques might con-
sider evaluating I
2 estimations when considering SD
units vs MID units.
Limitations of the method
Our method requires that previous investigations have
generated an estimate of the MID; this is true for only a
limited number of HRQL measures. Nevertheless, MIDs
are being increasingly established for instruments used
to evaluate common illnesses [18,19]. If an anchor-based
MID has not been established, distribution-based meth-
ods might provide a reasonable alternative for MID esti-
mation [20]. Because one or more measures of
variability are almost always available, distribution-based
MIDs are relatively easy to generate [21]. Nevertheless,
the circumstances in which distribution-based methods
concur with anchor-based methods, and the ideal distri-
bution-based method to use, remains unclear.
Even if the MID is available, application of the method
in particular instances may present challenges. In the
e x a m p l ew eh a v eu s e d ,t h eC R Qw a sn o to r i g i n a l l y
developed to provide an overall summary score, and for
this reason the majority of included trials calculated
estimates for each domain separately. We felt comforta-
ble with this strategy because previous work has demon-
strated that an overall score is sensible and likely
remains valid and responsive [22]. An additional limita-
tion is that, as described above, MID units are vulner-
able to naïve, oversimplified interpretation. Vulnerability
to misinterpretation is not, however, unique to the MID
a p p r o a c h .W eh a v es u g g e s t e dar u l e - o f - t h u m bg u i d et o
the interpretation of MID units, a guide that is some-
what arbitrary. Repeated experience using MID units, in
particular examining the relation between MID unit
effect and the difference in proportion of patients
demonstrating an improvement of at least 1 MID unit
in intervention and control groups, will further enhance
and refine the interpretability of the MID approach.
Conclusion
Systematic reviews and meta-analyses of randomized
trials that employ HRQL instruments provide the least
biased and most precise summary estimates of the impact
of interventions on patients’ lives. When, however,
Figure 2 Pooled Estimate in MID Units.
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instruments for the same construct, existing methods for
combining across studies are plagued by statistical and
interpretational limitations. The MID approach provides
a potential solution to the limitations of the existing
methods.
Additional material
Additional file 1: Total CRQ score formulas and MID units formulas.
Total CRQ score formulas: Standard errors and standard deviations for
total CRQ scores. MID units formulas: Pooling MID standardized mean
differences
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